查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1271182

杜氏肌營養不良症治療市場：按治療方法/治療類型、最終用戶、地區 - 規模、份額、前景、機會分析，2023-2030 年

Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

杜氏肌營養不良症 (DMD) 是一種肌營養不良症。 DMD 是一種遺傳性疾病，其特徵是進行性肌肉退化和無力，這是由於一種叫做抗肌萎縮蛋白的蛋白質發生變化，這種蛋白質可以防止肌肉細胞受損。 DMD 影響肌肉，導致肌肉無力隨著時間的推移變得更糟。 杜氏肌營養不良症主要影響男性，但在極少數情況下也可能發生在女性身上。

市場動態：

杜興氏肌營養不良症 (DMD) 患病率的增加、對新藥和治療的需求增加、研究和開發 (R&D) 的增加、公眾對 DMD 和可用藥物/治療的認識的提高，是預計會促進 DMD 增長的主要因素全球杜氏肌營養不良症治療市場。

例如，2022 年 5 月，Stealth BioTherapeutics Corp. 宣布美國食品和藥物管理局 (FDA) 授予 Elamipretide 孤兒藥資格，用於治療杜氏肌營養不良症 (DMD)。

此外，2022 年 4 月，輝瑞公司將在美國開展第一項 3 期研究，評估針對杜氏肌營養不良症 (DMD) 門診患者的研究性微型抗肌萎縮蛋白基因療法 fordadistrogene movaparvovec。我們計劃開設一個網站。

這項研究的主要特點

  • 本報告對杜氏肌營養不良症治療市場進行了深入分析，提供了以 2022 年為基準年的預測期（2023 年至 2030 年）的市場規模和復合年增長率 (CAGR %)。
  • 它還闡明了各個細分市場的潛在創收機會，並概述了該市場具有吸引力的投資建議矩陣。
  • 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 根據以下參數（包括公司亮點、產品組合、主要亮點、財務業績和戰略）介紹全球杜氏肌營養不良症治療市場的主要參與者。
  • 參與這項研究的主要公司包括輝瑞公司、BioMarin、Sarepta Therapeutics、Santhera Pharmaceuticals、PTC Therapeutics、Fibrogen Inc.、NS Pharma Inc.、Nobelpharma Co. Ltd.、Bristol-Myers Squibb 和 Eli Lilly和公司。
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
  • 《全球杜氏肌營養不良症療法市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球杜氏肌營養不良症治療市場的各種戰略矩陣來促進他們的決策。

這是目錄：

第一章調查的目的和前提

  • 調查的目的
  • 先決條件
  • 縮寫

第二章市場展望

  • 報告概述
    • 市場定義和範圍
  • 執行摘要
    • 市場概況：按治療方法和治療類型分類
    • 市場概況：按最終用戶分類
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 杜氏肌營養不良症患病率上升
    • 缺乏標準化和嚴格的規章制度
    • 對新藥和新療法的需求增加
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章杜氏肌營養不良療法的全球市場——冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 流行病學數據
  • 供應方和需求方分析
  • 經濟影響

第 5 章全球杜氏肌營養不良症治療市場：按治療方法和治療類型分類，2017-2030

  • 分子療法
  • 類固醇療法
  • 非甾體抗炎藥 (NSAID)
  • 其他治療方法和治療類型

第 6 章全球杜氏肌營養不良症治療市場：按最終用戶分類，2017-2030

  • 醫院/診所
  • 門診中心
  • 其他最終用戶

第 7 章。2017-2030 年按地區分列的全球杜氏肌營養不良症治療市場

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第八章競爭格局

  • Pfizer Inc.
  • Fibrogen Inc.
  • BioMarin
  • Sarepta Therapeutics
  • Santhera Pharmaceuticals
  • PTC Therapeutics
  • NS Pharma Inc.
  • Nobelpharma Co. Ltd.
  • Bristol-Myers Squibb
  • Eli Lilly and Company

第 9 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI898

Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.

Market Dynamics:

Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.

For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).

Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).

Key features of the study:

  • This report provides in-depth analysis of the Duchenne muscular dystrophy treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.

Detailed Segmentation:

  • Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type
    • Molecular-based Therapies
    • Steroid Therapy
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Other Therapeutic Approaches and Treatment Types
  • Global Duchenne Muscular Dystrophy Treatment Market, By End User
    • Hospitals/Clinics
    • Ambulatory Centers
    • Other End Users
  • Global Duchenne Muscular Dystrophy Treatment Market, By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Pfizer Inc.
    • Fibrogen Inc.
    • BioMarin
    • Sarepta Therapeutics
    • Santhera Pharmaceuticals
    • PTC Therapeutics
    • NS Pharma Inc.
    • Nobelpharma Co. Ltd.
    • Bristol-Myers Squibb
    • Eli Lilly and Company

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapeutic Approach and Treatment Type
    • Market Snapshot, By End User
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of Duchenne muscular dystrophy
    • Lack of standardization and stringent rules/regulations
    • Increase in demand for novel drugs or therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Duchenne Muscular Dystrophy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Molecular-based Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Steroid Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Therapeutic Approaches and Treatment Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospitals/Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Ambulatory Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other End Users
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Duchenne Muscular Dystrophy Treatment Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fibrogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BioMarin
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sarepta Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Santhera Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PTC Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NS Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Nobelpharma Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us